First-in-class Drug Iberdomide Approved for Multiple Myeloma
The new agent was approved in combination with daratumumab and hyaluronidase-fihj and dexamethasone for patients with resistant or refractory...
Progress Against Cancer
The new agent was approved in combination with daratumumab and hyaluronidase-fihj and dexamethasone for patients with resistant or refractory...
Vusolimogene oderparepvec-wtpg and nivolumab earned accelerated approval to treat patients with advanced melanoma after PD-1 therapy. The U.S. Food...
Lutetium Lu 177 vipivotide tetraxetan is the first radioligand therapy approved for metastatic prostate cancer that responds to hormone...
Zidesamtinib, a next-generation ROS1 inhibitor, was approved for ROS1-positive NSCLC previously treated with ROS1 inhibition. The U.S. Food and...
Gedatolisib received its first FDA approval for advanced HR-positive, HER2-negative breast cancer without mutations in PIK3CA. The U.S. Food...
The RET inhibitor received traditional approval to treat RET-fusion-positive solid tumors. The U.S. Food and Drug Administration (FDA) has...
FDA approves pembrolizumab and enfortumab vedotin-ejfv for patients with muscle-invasive bladder cancer regardless of cisplatin eligibility. The U.S. Food...
The FDA approved isatuximab-irfc as part of three different combination regimens for multiple myeloma. The U.S. Food and Drug...
The allogeneic regulatory T cell therapy was designed to improve HSCT outcomes in patients with hematological malignancies. The U.S....
Sacituzumab govitecan-hziy was approved as a monotherapy or in combination with pembrolizumab. The U.S. Food and Drug Administration (FDA)...